Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SpainBack to Spain

Clinical trials in Pontevedra – page 5

65 clinical trials in Pontevedra, Spain. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Pontevedra at a glance
65
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

65 trials in Pontevedra

Open in trial search

Hidradenitis

Not recruiting

Study on the Long-Term Safety of Povorcitinib for Patients with Moderate to Severe Hidradenitis Suppurativa

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:4-[3-(Cyanomethyl)-3-(3',5'-Dimethyl-1H,1'H-[4,4'-Bipyrazol]-1-Yl)Azetidin-1-Yl]-2,5-Difluoro-N-[(2S)-1,1,1-Trifluoropropan-2-Yl]Benzamide
  • Sponsor:Incyte Corp.

Colitis ulcerative

Not recruiting

Study on the Effects of Guselkumab and Golimumab for Patients with Moderate to Severe Ulcerative Colitis

Investigational
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Golimumab
  • Sponsor:Janssen Cilag International

Psoriasis

Not recruiting

Study on Adjustable Brodalumab Dosage for Patients with Moderate-to-Severe Plaque Psoriasis Weighing 120 kg or More

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Brodalumab
  • Sponsor:Leo Pharma A/S

Dermatitis atopic

Not recruiting

Study on Dose Flexibility of Upadacitinib for Adults with Moderate to Severe Atopic Dermatitis

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Upadacitinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Colorectal cancer metastatic+1

Not recruiting

Study on Preventing Blood Clots with Tinzaparin in Patients with Metastatic Colorectal Cancer Starting First-Line Treatment

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Tinzaparin Sodium
  • Sponsor:Grupo Gallego De Investigacion En Tumores Digestivos

Pulmonary tuberculosis

Not recruiting

Study on the Effectiveness and Safety of High-Dose Rifampicin, Moxifloxacin, and Linezolid for Patients with Pulmonary Tuberculosis

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Cyanocobalamin
  • Sponsor:Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca

End stage renal disease+1

Not recruiting

Study Comparing Rifampicin, Isoniazid, and Rifapentine Regimens for Treating Latent Tuberculosis in Patients with End-Stage Kidney Disease

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Isoniazid
  • Sponsor:Bellvitge University Hospital

Anal fistula

Not recruiting

Study on the Long-Term Safety of Darvadstrocel for Adults with Crohn's Disease and Complex Perianal Fistulas

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells Expanded
  • Sponsor:Takeda Development Center Americas Inc.

Chronic hepatitis B+1

Not recruiting

Study of Bepirovirsen for Patients with Chronic Hepatitis B on Nucleos(t)ide Analogue Treatment

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bepirovirsen
  • Sponsor:Glaxosmithkline Research & Development Limited

Hidradenitis

Not recruiting

Study on the Effectiveness and Safety of Povorcitinib for Patients with Moderate to Severe Hidradenitis Suppurativa

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:4-[3-(Cyanomethyl)-3-(3',5'-Dimethyl-1H,1'H-[4,4'-Bipyrazol]-1-Yl)Azetidin-1-Yl]-2,5-Difluoro-N-[(2S)-1,1,1-Trifluoropropan-2-Yl]Benzamide
  • Sponsor:Incyte Corp.

Colitis ulcerative

Not recruiting

Study on the Effects of Obefazimod for Patients with Moderate to Severe Ulcerative Colitis

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Obefazimod
  • Sponsor:Abivax

Portal hypertension

Not recruiting

Study on BI 685509 and Empagliflozin for Patients with Portal Hypertension in Compensated Cirrhosis

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:BI 685509
  • Sponsor:Boehringer Ingelheim Espana S.A.

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Pontevedra

What the registry says about research in the country

01 Infectious Diseases

Clinical studies focusing on tuberculosis treatments, including innovative approaches for both latent and active forms of the disease in special patient populations.

  • Pulmonary tuberculosis treatment optimization
  • Latent TB in kidney disease patients
  • Novel drug combinations

Research evaluating the effectiveness of various rifamycin-based regimens and high-dose antibiotic combinations.

02 Hepatology

Extensive research into liver diseases, particularly focusing on non-alcoholic steatohepatitis (NASH) and chronic hepatitis B treatments.

  • NASH therapy development
  • Chronic hepatitis B management
  • Liver fibrosis treatment

Multiple studies evaluating novel therapeutic approaches and combination treatments for liver conditions.

03 Dermatology & Immunology

Innovative research in inflammatory skin conditions and immune-mediated disorders, including studies on atopic dermatitis and urticaria.

  • Atopic dermatitis treatment
  • Chronic urticaria management
  • Hidradenitis suppurativa therapy

Investigation of new targeted therapies and dose optimization studies for various skin conditions.

Back to SpainAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.